劉雪聰 ,劉福林,李志林,周曉東,申文增,周程
(1河北大學(xué)附屬醫(yī)院,河北保定071000;2河北大學(xué)化學(xué)院;3河北大學(xué)生理教研室)
·論著·
氫氣對(duì)大鼠離體心肌缺血再灌注損傷的保護(hù)作用及機(jī)制
劉雪聰1,劉福林1,李志林2,周曉東1,申文增3,周程1
(1河北大學(xué)附屬醫(yī)院,河北保定071000;2河北大學(xué)化學(xué)院;3河北大學(xué)生理教研室)
目的 探討氫氣對(duì)心肌缺血再灌注(I/R)損傷的保護(hù)作用。方法 將48只大鼠隨機(jī)分為實(shí)驗(yàn)組和對(duì)照組各24只。取兩組大鼠心臟,按逆灌注10 min,常溫曠置20 min、再灌注20 min的方法建立心肌缺血再灌注模型。對(duì)照組灌注液用K-R液,實(shí)驗(yàn)組灌注液用K-R液+氫氣飽和生理鹽水。監(jiān)測(cè)兩組大鼠心臟缺血前期、缺血期、再灌注期心肌組織丙二醛(MDA)、超氧化物歧化酶(SOD)水平及左室舒張末期壓力(LVEDP)。結(jié)果 對(duì)照組缺血期心肌MDA水平高于缺血前期(P<0.05),再灌注期心肌MDA水平低于缺血期(P<0.05),但仍高于缺血前期(P<0.05)。實(shí)驗(yàn)組各期心肌MDA水平無(wú)統(tǒng)計(jì)學(xué)差異;缺血期、再灌注期心肌MDA水平較對(duì)照組同期下降(P均<0.05)。兩組缺血期與缺血前期心肌SOD水平無(wú)統(tǒng)計(jì)學(xué)差異,缺血再灌注期心肌SOD水平低于缺血前期和缺血期(P均<0.05)。實(shí)驗(yàn)組缺血期與再灌注期心肌SOD水平較對(duì)照組同期升高(P均<0.05)。對(duì)照組再灌注期LVEDP高于缺血前期(P<0.05);實(shí)驗(yàn)組再灌注期與缺血前期LVEDP無(wú)統(tǒng)計(jì)學(xué)差異,但與對(duì)照組同期比較下降明顯(P<0.05)。結(jié)論 氫氣對(duì)大鼠離體心臟心肌I/R損傷有明顯的保護(hù)作用。其機(jī)制可能為抑制心肌組織MDA表達(dá),提高心肌組織SOD水平。
心肌缺血再灌注損傷;氫氣飽和生理鹽水;丙二醛;超氧化物歧化酶
體外循環(huán)下心臟直視手術(shù)時(shí)心臟會(huì)經(jīng)歷缺血再灌注(I/R)的過(guò)程,而I/R損傷會(huì)引起心肌頓抑、心律失常等[1]。研究證實(shí),自由基、鈣超載、心肌纖維能量代謝障礙、細(xì)胞凋亡等均可參與心肌I/R損傷。氫氣對(duì)羥自由基及過(guò)氧亞硝基等陰離子有中和作用[3],可作為抗氧化劑用于腦缺血所致的I/R損傷[4]。2014年6~10月,我們觀察了氫氣飽和鹽水對(duì)大鼠離體心臟I/R損傷的保護(hù)作用,現(xiàn)分析結(jié)果并探討其作用機(jī)制。
1.1 材料 實(shí)驗(yàn)動(dòng)物為 Wistar大鼠48只,雌雄不限,體質(zhì)量200~350 g,由中國(guó)人民解放軍軍事醫(yī)學(xué)科學(xué)院衛(wèi)生學(xué)環(huán)境醫(yī)學(xué)研究所動(dòng)物實(shí)驗(yàn)中心提供,合格證號(hào):SCXK-(軍)2009-003。實(shí)驗(yàn)用氫氣為自制,由河北大學(xué)化學(xué)院李志林老師提供(制備技術(shù)已獲得國(guó)家專(zhuān)利,專(zhuān)利號(hào)ZL102557227B),氫氣飽和生理鹽水(pH值為7.3);丙二醛(SOD)、超氧化物歧化酶(MDA)檢測(cè)試劑盒和考馬斯亮藍(lán)蛋白試劑盒均購(gòu)自南京建成生物工程研究所。
1.2 實(shí)驗(yàn)方法
1.2.1 模型制備及干預(yù) 將48只大鼠隨機(jī)分為對(duì)照組與實(shí)驗(yàn)組,每組24只。 按大鼠體質(zhì)量注射戊巴比妥鈉(30 mg/kg)麻醉、肝素(250 U/kg)抗凝。待麻醉起效后,迅速沿劍突下肋緣剪開(kāi)腹壁并打開(kāi)膈肌,同時(shí)將兩側(cè)腋前線剪開(kāi)胸壁并將其上翻至頭側(cè),在不影響主動(dòng)脈的情況下,摘取心臟,立即放入4 ℃冰鹽水中,并輕壓心臟,洗去血跡。將離體心臟按逆灌注10 min、常溫曠置20 min、再灌注20 min的順序進(jìn)行I/R。行主動(dòng)脈插管并將離體心臟固定于Langendorff裝置,將預(yù)先用氧平衡的37 ℃灌注液以7.85 kPa灌注壓進(jìn)行心臟灌注,同時(shí)在左心耳處剪一小口,并經(jīng)二尖瓣處將帶有乳膠氣囊的測(cè)壓管插入左心室,同時(shí)連接BL-420生物技能實(shí)驗(yàn)系統(tǒng),將氣囊內(nèi)壓力調(diào)至7 mmHg 。對(duì)照組采用K-R液灌注,實(shí)驗(yàn)組采用K-R液+氫氣飽和生理鹽水(5 mL/kg,pH值為7.3)灌注。
1.2.2 相關(guān)指標(biāo)觀察 兩組均于缺血前期、缺血期和再灌注期各取8個(gè)離體心臟,將心肌組織剪下,并經(jīng)生理鹽水漂洗后勻漿。采用721型分光光度計(jì)比色測(cè)定心肌組織MDA、SOD水平,嚴(yán)格按試劑盒說(shuō)明書(shū)操作;采用BL-420生物技能實(shí)驗(yàn)系統(tǒng)記錄缺血前期及再灌注期左室舒張末期壓力(LVEDP)。
兩組各期LVEDP及心肌組織MDA、SOD水平見(jiàn)表1。由表1可見(jiàn),對(duì)照組缺血期心肌MDA水平高于缺血前期(P<0.05),再灌注期心肌MDA水平低于缺血期(P<0.05),但仍高于缺血前期(P<0.05)。實(shí)驗(yàn)組各期心肌MDA水平無(wú)統(tǒng)計(jì)學(xué)差異;缺血期、再灌注期心肌MDA水平較對(duì)照組同期下降(P均<0.05)。兩組缺血期與缺血前期心肌SOD水平無(wú)統(tǒng)計(jì)學(xué)差異,缺血再灌注期心肌SOD水平低于缺血前期和缺血期(P均<0.05)。實(shí)驗(yàn)組缺血期與缺血再灌注期心肌SOD水平較對(duì)照組同期升高(P均<0.05)。對(duì)照組再灌注期LVEDP高于缺血前期(P<0.05);實(shí)驗(yàn)組再灌注期與缺血前期LVEDP無(wú)統(tǒng)計(jì)學(xué)差異,但與對(duì)照組同期比較下降明顯(P<0.05)。
表1 兩組I/R過(guò)程中心肌MDA、SOD水平及LVEDP比較
本研究結(jié)果顯示,氫氣可降低心肌中MDA,提高SOD活性,改善缺血再灌注大鼠的心功能。此種心肌保護(hù)作用可能與之前報(bào)導(dǎo)的大腦損傷模型中分子氫選擇性清除活性氧簇(ROS)有關(guān)[5]。I/R過(guò)程中心肌細(xì)胞可產(chǎn)生一系列活性氧簇(ROS),其中羥自由基(·OH)和過(guò)氧化亞硝酸陰離子(ONOO-)是有害自由基,可與不飽和脂肪酸作用引發(fā)脂質(zhì)過(guò)氧化反應(yīng),其產(chǎn)物可破壞具有重要功能的生物大分子(如DNA、蛋白質(zhì)、脂類(lèi)等)的結(jié)構(gòu)和功能。導(dǎo)致致死性的再灌注損傷[6~8]。線粒體是產(chǎn)生ROS的主要部位,而一些大分子進(jìn)入線粒體困難[9]。研究發(fā)現(xiàn),氫氣可清除氧自由基[5]。氫氣分子是電中性的,分子量小于氧氣分子,可穿過(guò)細(xì)胞膜進(jìn)入細(xì)胞核和細(xì)胞器如細(xì)胞核及線粒體中。氫分子能夠通過(guò)細(xì)胞膜進(jìn)入胞內(nèi)清除自由基,這一特性是其他抗氧化劑所不具備的[5]。本研究實(shí)驗(yàn)組心肌組織MDA水平低于對(duì)照組,SOD活性高于對(duì)照組,證實(shí)氫氣飽和生理鹽水對(duì)離體心臟心肌I/R損傷有保護(hù)作用,其機(jī)制可能為迅速使心肌細(xì)胞氫氣濃度上升,氫氣減少了ROS的產(chǎn)生、穩(wěn)定線粒體膜電位、維持ATP穩(wěn)定的合成、避免了DNA損傷、降低了脂質(zhì)過(guò)氧化物MDA生成,從而保護(hù)了心肌。其中發(fā)揮保護(hù)作用的最根本機(jī)制可能是抑制線粒體通透性轉(zhuǎn)換孔開(kāi)放[10,11]。
心肌缺血后心功能的變化表現(xiàn)為靜止張力(如LVEDP)隨缺血時(shí)間的延長(zhǎng)逐漸增高(表現(xiàn)為L(zhǎng)VEDP升高),再灌注時(shí)繼續(xù)增高;缺血心肌在恢復(fù)血液灌注后一段時(shí)間內(nèi)出現(xiàn)可逆性收縮功能減低現(xiàn)象,稱(chēng)之為心肌頓抑。本研究結(jié)果顯示,實(shí)驗(yàn)組再灌注期LVEDP低于缺血前期和對(duì)照組再灌注期,表明氫氣可以降低I/R導(dǎo)致的心肌頓抑程度,促進(jìn)患者心功能恢復(fù)。氧化應(yīng)激是引起心肌I/R損傷的首要因素。減輕氧化應(yīng)激被認(rèn)為是保護(hù)心肌細(xì)胞的重要措施。氫氣的易擴(kuò)散性可以使其與羥自由基反應(yīng)產(chǎn)生成水[12],所以可以清除ROS。在以前的醫(yī)學(xué)應(yīng)用中氫氣僅限于檢測(cè)抗菌治療的效果[13]。雖然也有動(dòng)物實(shí)驗(yàn)研究證明其他的給氫方式可以有效清除活性氧,但進(jìn)入臨床研究后幾乎都失敗了[14]。近年來(lái),隨著氫氣在生物體內(nèi)功能的深入研究,人們發(fā)現(xiàn)其在減輕心肌I/R損傷中具有明顯的作用[15]。基于以上理論基礎(chǔ),本研究通過(guò)建立離體Langendorff模型,對(duì)氫氣飽和生理鹽水在心肌I/R損傷中的作用做進(jìn)一步研究,為找尋體外循環(huán)中所造成的心肌I/R的保護(hù)方法,將為氫氣飽和生理鹽水用于體外循環(huán)心臟直視手術(shù)的心肌保護(hù)提供實(shí)驗(yàn)資料。本研究結(jié)果顯示,氫氣飽和生理鹽水可減輕心肌I/R損傷,提高左心室舒張壓及收縮壓,但由于實(shí)驗(yàn)仍處于基礎(chǔ)研究水平,還需進(jìn)一步研究明確其臨床應(yīng)用效果。
[1] 劉福林,周玉娟,武變英.1,6-二磷酸果糖對(duì)心肌缺血再灌注損傷的保護(hù)[J].心血管病學(xué)進(jìn)展,2004,25(5):342-344.
[2] 王永維,韓敏.舒血寧治療老年冠心病心肌缺血10例臨床觀察[J].吉林大學(xué)學(xué)報(bào):醫(yī)學(xué)版, 2013,39(3):502.
[3] 劉穎,孫強(qiáng),張威,等.氫氣飽和生理鹽水對(duì)大鼠腦缺血再灌注損傷的保護(hù)作用[J].第二軍醫(yī)大學(xué)學(xué)報(bào),2010,31(3):238-241.
[4] 孫學(xué)軍,J Zhang JH.氫—一種內(nèi)源性抗氧化劑[J].第二軍醫(yī)大學(xué)學(xué)報(bào),2008,29(3):233-235.
[5] Ohsawa I, Ishikawa M, Takahashi K, et al. Hydrogen acts as a therapeutic antioxidant by selectively reducing cytotoxic oxygen radicals[J]. Nat Med, 2007,13(6):688-694.
[6] Zweier JL, Flaherty JT, Weisfeldt ML. Direct measurement of free radical generation following reperfusion of ischemic myocardium[J]. Proc Natl Acad Sci USA, 1987,84(5):1404-1407.
[7] Bolli R, Patel BS, Jeroudi MO, et al. Demonstration of free radical generation in "stunned" myocardium of intact dogs with the use of the spin trap alpha-phenyl N-tert-butyl nitrone[J]. J Clin Invest, 1988,82(2):476-485.
[8] Vanden-Hoek T, Becker LB, Shao ZH, et al. Preconditioning in cardiomyocytes protects by attenuating oxidant stress at reperfusion[J]. Circ Res, 2000,86(5):541-548.
[9] Maher P, Salgado KF, Zivin JA, et al. A novel approach to screening for new neuroprotective compounds for the treatment of stroke[J]. Brain Res, 2007,1173:117-125.
[10] Javadov S, Karmazyn M. Mitochondrial permeability transition pore opening as an endpoint to initiate cell death and as a putative target for cardioprotection[J]. Cell Physiol Biochem, 2007,20(1-4):1-22.
[11] Griffiths EJ, Halestrap AP. Mitochondrial non-specific pores remain closed during cardiac ischaemia, but open upon reperfusion[J]. Biochem J, 1995, 307(1):93-98.
[12] Labiche LA, Grptta JC. Clinical trials for cytoprotection in stroke[J]. Neuror, 2004,1(1):46-70.
[13] Sobko T, Elfstrom K, Naver L, et al. Intestinal hydrogen and nitric oxide gases in preterm infantseffects of antibiotic therapy[J]. Neonatology, 2009,95(1):68-73.
[14] Bolli R, Becker L, Gross G, et al. Myocardial protection at a crossroads: the need for translation into clinical therapy[J]. Circ Res, 2004,95(2):125-134.
[15] Sun Q, Kang ZM, Cai JM, et al. Hydrogen-rich saline protects myocardium against ischemia/reperfusion injuryin rats[J]. Exp Biol Med (Maywood), 2009,234(10):1212-1219.
Protective effects of hydrogen saturated saline alleviating myocardial ischemia reperfusion injury in rats
LIUXue-cong1,LIUFu-lin,LIZhi-lin,ZHOUXiao-dong,SHENWen-zeng,ZHOUCheng
(AffiliatedHospitalofHebeiUniversity,Baoding071000,China)
Objective To explore the protective effects of hydrogen saturated saline in induced myocardial ischemia reperfusion injury in rats. Methods Forty-eight rats were divided randomly into the experimental group (24) and the control group (24). The rats of experimental group were treated with K-R solution combined with hydrogen saturated saline, the controls were given K-R solution only. After the treatment, the hearts were excised rats and Langendorff model. And the heart of the in vitro by inverse perfusion for 10 minutes, normal temperature place for 20 minutes, 20 minutes of reperfusion.The solution of the cardiac muscle tissue of the rats were treated with saline and then the accounts of malondialdehyde (MDA)and the activity of superoxide dismutase(SOD) , and the changes of left ventricular end-diastolic pressure (LVEDP) were determined to compare the different protective effects. Results The accounts of MDA in the control group were the highest, there was a significant difference between the experimental group and the controls concerning with the results of ischemia period and reperfusion period (P<0.01,P<0.05). There were differences among the ischemia period and reperfusion period and preischemia period in the control group(P<0.05). In the experimental group, there was not significant difference among the ischemia period and reperfusion period and the preischemia period. There was a significant difference between the experimental group and the controls considering the activity of SOD (P<0.01). The accounts of LVEDP of the control group was obviously high (P<0.05). The level of LVEDP in experimental group was obviously lower than in the control group (P<0.05),but had no significant difference to ischemia period. Conclusion Hydrogen rich saline is quite effective in alleviating myocardial ischemia reperfusion injury.
myocardial ischemia reperfusion injury;hydrogen-rich saline; malondialdehgde; superoxide dismutase
河北省2013年醫(yī)學(xué)科學(xué)研究重點(diǎn)課題計(jì)劃項(xiàng)目(20130369)。
劉雪聰(1987-),男,在讀碩士,研究方向?yàn)樾募∪毖俟嘧p傷、冠狀動(dòng)脈粥樣斑塊易損性和冠心病的外科治療。E-mail:314678161@qq.com
劉福林(1966-),男,主任醫(yī)師,教授,碩士生導(dǎo)師,研究方向?yàn)樾募∪毖俟嘧p傷、冠狀動(dòng)脈粥樣斑塊易損性和冠心病的外科治療。E-mail:lful666@sina.com
10.3969/j.issn.1002-266X.2015.06.001
R34
A
1002-266X(2015)06-0001-03
2014-12-13)